American Association for Cancer Research
crc-22-0293-s20.pdf (133.56 kB)

Supplementary Table 5 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade

Download (133.56 kB)
journal contribution
posted on 2023-08-16, 14:20 authored by Sapna Yadavilli, Jeremy D. Waight, Sara Brett, Meixia Bi, Tianqian Zhang, Yao-Bin Liu, Catherine Ellis, David C. Turner, Ashleigh Hahn, Hong Shi, Laura Seestaller-Wehr, Junping Jing, Qing Xie, Jafar Sadik Shaik, Xiao Ji, Robert Gagnon, William Fieles, Laura Hook, Steven Grant, Stephanie Hopley, M. Phillip DeYoung, Christina Blackwell, Michael Chisamore, Robert Biddlecombe, David J. Figueroa, Christopher B. Hopson, Roopa Srinivasan, James Smothers, Michele Maio, Danny Rischin, Daniel Olive, Elaine Paul, Patrick A. Mayes, Axel Hoos, Marc Ballas

Pearson correlation (r) analysis of ICOS versus PD-L1 (CD274) in different tumor type.


GlaxoSmithKline (GSK)



Stimulation of the T-cell activation marker ICOS with the anti-ICOS agonist mAb feladilimab, alone and in combination with PD-1 inhibition, induces antitumor activity across nonclinical models as well as select patients with advanced solid tumors.